We’re moving people out of the criminal justice system instead of into it, we’re saving resources, we’re saving taxpayer ...

AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about ...

AbbVie Inc (NYSE: ABBV) saw its stock fall nearly 13% after reporting disappointing mid-stage trial results for emraclidine, ...

Jacob Ballon, MD, MPH, of Stanford University in California, discussing research evaluating the impact of different antipsychotics on the cognitive symptoms of schizophrenia. "There is no clear ...

The S&P 500 Index ($SPX) (SPY) today is up +0.21%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +1.02%, and the Nasdaq ...

The S&P 500 Index ($SPX) (SPY) Monday closed up +0.10%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.69%, and ...

The most common side effects of INVEGA HAFYERA® include: injection site reactions, weight gain, headache, upper respiratory ...

Among individuals with schizophrenia, the risk for natural-cause mortality was increased in those with reduced cognitive functioning.

Researchers have developed a potential diagnostic tool for schizophrenia by observing how patients process conflicting information.

Shares of AbbVie (ABBV) are sinking on Monday after the company said two mid-stage trials of its investigative treatment for adults with schizophrenia missed their primary endpoints. AbbVie’s ...

Teva Pharmaceuticals’ TEV-‘749 (olanzapine) has shown statistical improvement in schizophrenia symptoms in a Phase III trial. The Phase III SOLARIS trial (NCT05693935) demonstrated ...

Advancing two pivotal Phase 3 trials of BXCL501 for acute treatment of agitation associated with bipolar disorders, ...